抗血小板药:现状、挑战及趋势

Antiplatelet:Current State,Challenge and Chance

动脉血栓性疾病冠心病和缺血性中风危害极大,为人类健康的首位杀手,抗血小板药效果肯定,但现有抗血小板药存在疗效不稳定、不满意、有出血副作用等问题。我们仍然需要抗血栓效果更好、出血副作用更小的抗血小板药。研发具有新的作用机制的抗血小板药、研究血小板激活的机制、发现新的抗血小板药的靶点有助于研发更加安全、有效的抗血小板新药。本文拟就现有的抗血小板药、正在研发阶段的抗血小板药作简要介绍。

Antiplatelet therapy has been established as a cornerstone in the management of arterial thrombotic diseases including ischemic heart disease,the No.1 killer worldwide. Despite the proven benefits of currently available antiplatelet drugs,there are still recurrent ischemic events;morbidity and mortality are still high. Moderate efficacy,response variability,and the bleeding risk are the major challenge;there is still much room for further improvement of antiplatelet treatment and development of novel antiplatelet agents with increased efficacy and safety profile. Intensive study on the mechanism underlying platelet activation,exploration of new antiplatelet agents with novel mechanism,and seeking novel targets for antiplatelet R D should provide new chance for more efficacious and safer antiplatelet drugs.This review will summarize the current state of antiplatelet agents marketed and under development,the challenge and chance for R D of novel antiplatelet agents.